Introduction
•Understand the mechanism of action of Mounjaro, a once-weekly, first-in-class GIP and GLP-1 receptor agonist for chronic weight management and type 2 diabetes.
•Review the efficacy and safety of Mounjaro in chronic weight management and type 2 diabetes.
•Review the efficacy superiority of Mounjaro (Tirzepatide) compared with Wegovy (Semaglutide) in chronic weight management.
•Discuss the safe and effective use of Mounjaro.
Objectives
•Understand the mechanism of action of Mounjaro, a once-weekly, first-in-class GIP and GLP-1 receptor agonist for chronic weight management and type 2 diabetes.
•Review the efficacy and safety of Mounjaro in chronic weight management and type 2 diabetes.
•Review the efficacy superiority of Mounjaro (Tirzepatide) compared with Wegovy (Semaglutide) in chronic weight management.
•Discuss the safe and effective use of Mounjaro.
This Course For :
Clinical Pharmacy
Pharmacy
Speaker
Bassem Mohamed Abdel-Maksoud
Executive Manager, CardioMetabolic at Eli Lilly Saudi Arabia
Provided by :
Price
Course Fee
FREE
FREE
Contact Information
Organization : Virtual Medical AcademyPhone : 920008161
Email : [email protected]
Free
10 Sep 2025 To 10 Sep 2025 -
07:00 PM To 09:00 PM 
Certificate Available 
Online
- 53
Add to Calendar
09/10/2025 07:00 PM
09/10/2025 09:00 PM
Asia/ Riyadh
Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes
Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist for Chronic Weight Management and Type 2 Diabetes
https://medicalacademy.org/portal/event/view/2451
